Christopher P. Evans

21.7k total citations · 2 hit papers
250 papers, 10.3k citations indexed

About

Christopher P. Evans is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Cancer Research. According to data from OpenAlex, Christopher P. Evans has authored 250 papers receiving a total of 10.3k indexed citations (citations by other indexed papers that have themselves been cited), including 171 papers in Pulmonary and Respiratory Medicine, 93 papers in Molecular Biology and 60 papers in Cancer Research. Recurrent topics in Christopher P. Evans's work include Prostate Cancer Treatment and Research (137 papers), Prostate Cancer Diagnosis and Treatment (40 papers) and Bladder and Urothelial Cancer Treatments (32 papers). Christopher P. Evans is often cited by papers focused on Prostate Cancer Treatment and Research (137 papers), Prostate Cancer Diagnosis and Treatment (40 papers) and Bladder and Urothelial Cancer Treatments (32 papers). Christopher P. Evans collaborates with scholars based in United States, Canada and United Kingdom. Christopher P. Evans's co-authors include Joy C. Yang, Allen C. Gao, Wei Lou, Chengfei Liu, Nagalakshmi Nadiminty, Hsing-Jien Kung, Ralph W. deVere White, Yezi Zhu, Primo N. Lara and Thenappan Chandrasekar and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and JAMA.

In The Last Decade

Christopher P. Evans

244 papers receiving 10.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

lncRNA-dependent mechanisms of androgen-receptor-regulated gene activation programs

2013 520 citations Joy C. Yang, Christopher P. Evans et al. profile →
Mechanisms of resistance in castration-resistant prostate cancer (CRPC).

2015 424 citations Thenappan Chandrasekar, Joy C. Yang et al. PubMed Central profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Christopher P. Evans United States	58	5.1k	4.9k	3.6k	1.8k	1.1k	250	10.3k
David F. Jarrard United States	49	4.0k 0.8×	5.0k 1.0×	2.0k 0.6×	2.1k 1.2×	920 0.8×	207	10.0k
Srinivasan Yegnasubramanian United States	52	6.3k 1.2×	3.8k 0.8×	2.7k 0.7×	1.6k 0.9×	709 0.6×	166	9.9k
Patricia Troncoso United States	62	3.9k 0.8×	8.0k 1.6×	2.5k 0.7×	4.4k 2.4×	1.7k 1.5×	256	13.8k
Chin‐Lee Wu United States	52	4.2k 0.8×	2.8k 0.6×	2.0k 0.5×	2.0k 1.1×	1.5k 1.3×	247	8.5k
G. Steven Bova United States	52	7.9k 1.5×	5.2k 1.1×	2.9k 0.8×	2.8k 1.5×	1.2k 1.1×	132	12.6k
Mototsugu Oya Japan	50	3.8k 0.7×	4.5k 0.9×	1.9k 0.5×	3.2k 1.8×	3.4k 3.0×	622	11.2k
Natasha Kyprianou United States	49	3.9k 0.8×	2.7k 0.6×	1.7k 0.5×	2.0k 1.1×	450 0.4×	135	7.5k
Wael Sakr United States	56	3.1k 0.6×	5.2k 1.1×	2.2k 0.6×	3.0k 1.6×	2.9k 2.5×	214	11.4k
Hirotsugu Uemura Japan	39	2.4k 0.5×	3.9k 0.8×	1.3k 0.4×	2.1k 1.2×	1.1k 0.9×	367	7.1k
Zoran Čulig Austria	61	5.5k 1.1×	5.7k 1.2×	2.9k 0.8×	3.2k 1.8×	612 0.5×	221	11.7k

Countries citing papers authored by Christopher P. Evans

Since Specialization

Citations

This map shows the geographic impact of Christopher P. Evans's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher P. Evans with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher P. Evans more than expected).

Fields of papers citing papers by Christopher P. Evans

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher P. Evans. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher P. Evans. The network helps show where Christopher P. Evans may publish in the future.

Co-authorship network of co-authors of Christopher P. Evans

This figure shows the co-authorship network connecting the top 25 collaborators of Christopher P. Evans. A scholar is included among the top collaborators of Christopher P. Evans based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christopher P. Evans. Christopher P. Evans is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Briggs, Paula, Christopher P. Evans, Steven Lane, et al.. (2025). Feasibility of developing a new tool for assessing vaginal health in women with Genitourinary Syndrome of Menopause; The VAN study. Post Reproductive Health. 31(3). 163–172.

Xu, Pengfei, Joy C. Yang, Bo Chen, et al.. (2023). Androgen receptor blockade resistance with enzalutamide in prostate cancer results in immunosuppressive alterations in the tumor immune microenvironment. Journal for ImmunoTherapy of Cancer. 11(5). e006581–e006581. 24 indexed citations

Ning, Shu, Chengfei Liu, Wei Lou, et al.. (2022). Bioengineered BERA-Wnt5a siRNA Targeting Wnt5a/FZD2 Signaling Suppresses Advanced Prostate Cancer Tumor Growth and Enhances Enzalutamide Treatment. Molecular Cancer Therapeutics. 21(10). 1594–1607. 16 indexed citations

Armstrong, Cameron M., Chengfei Liu, Liangren Liu, et al.. (2020). Steroid Sulfatase Stimulates Intracrine Androgen Synthesis and is a Therapeutic Target for Advanced Prostate Cancer. Clinical Cancer Research. 26(22). 6064–6074. 17 indexed citations

Aggarwal, Rahul, David A. Quigley, Jiaoti Huang, et al.. (2019). Whole-Genome and Transcriptional Analysis of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer Demonstrates Intraclass Heterogeneity. Molecular Cancer Research. 17(6). 1235–1240. 40 indexed citations

Liu, Chengfei, Joy C. Yang, Cameron M. Armstrong, et al.. (2019). AKR1C3 Promotes AR-V7 Protein Stabilization and Confers Resistance to AR-Targeted Therapies in Advanced Prostate Cancer. Molecular Cancer Therapeutics. 18(10). 1875–1886. 53 indexed citations

Cucchiara, Vito, Joy C. Yang, Chengfei Liu, et al.. (2019). GnRH Antagonists Have Direct Inhibitory Effects On Castration-Resistant Prostate Cancer Via Intracrine Androgen and AR-V7 Expression. Molecular Cancer Therapeutics. 18(10). 1811–1821. 10 indexed citations

Wang, Yongqiang, Zenghong Huang, Chengfei Liu, et al.. (2019). Therapeutic Targeting of MDR1 Expression by RORγ Antagonists Resensitizes Cross-Resistant CRPC to Taxane via Coordinated Induction of Cell Death Programs. Molecular Cancer Therapeutics. 19(2). 364–374. 19 indexed citations

Nguyen, Hao G., Crystal S. Conn, Lingru Xue, et al.. (2018). Development of a stress response therapy targeting aggressive prostate cancer. Science Translational Medicine. 10(439). 115 indexed citations

10.

Liu, Chengfei, Cameron M. Armstrong, Wei Lou, et al.. (2017). Niclosamide and Bicalutamide Combination Treatment Overcomes Enzalutamide- and Bicalutamide-Resistant Prostate Cancer. Molecular Cancer Therapeutics. 16(8). 1521–1530. 54 indexed citations

11.

Shi, Xu-Bao, Ai-Hong Ma, Lingru Xue, et al.. (2015). miR-124 and Androgen Receptor Signaling Inhibitors Repress Prostate Cancer Growth by Downregulating Androgen Receptor Splice Variants, EZH2, and Src. Cancer Research. 75(24). 5309–5317. 61 indexed citations

12.

Nadiminty, Nagalakshmi, Ramakumar Tummala, Chengfei Liu, et al.. (2015). NF-κB2/p52:c-Myc:hnRNPA1 Pathway Regulates Expression of Androgen Receptor Splice Variants and Enzalutamide Sensitivity in Prostate Cancer. Molecular Cancer Therapeutics. 14(8). 1884–1895. 100 indexed citations

13.

Chandrasekar, Thenappan, Joy C. Yang, Allen C. Gao, & Christopher P. Evans. (2015). Mechanisms of resistance in castration-resistant prostate cancer (CRPC).. PubMed Central. 4(3). 365–80. 424 indexed citations breakdown →

14.

Zhu, Yezi, Chengfei Liu, Nagalakshmi Nadiminty, et al.. (2013). Inhibition of ABCB1 Expression Overcomes Acquired Docetaxel Resistance in Prostate Cancer. Molecular Cancer Therapeutics. 12(9). 1829–1836. 104 indexed citations

15.

Nadiminty, Nagalakshmi, Ramakumar Tummala, Chengfei Liu, et al.. (2013). NF-κB2/p52 Induces Resistance to Enzalutamide in Prostate Cancer: Role of Androgen Receptor and Its Variants. Molecular Cancer Therapeutics. 12(8). 1629–1637. 156 indexed citations

16.

Ganti, Sheila, Sandra L. Taylor, Omran Abu Aboud, et al.. (2012). Kidney Tumor Biomarkers Revealed by Simultaneous Multiple Matrix Metabolomics Analysis. Cancer Research. 72(14). 3471–3479. 100 indexed citations

17.

Nadiminty, Nagalakshmi, Wei Lou, Meng Sun, et al.. (2010). Aberrant Activation of the Androgen Receptor by NF-κB2/p52 in Prostate Cancer Cells. Cancer Research. 70(8). 3309–3319. 91 indexed citations

18.

Gautschi, Oliver, Clifford G. Tepper, Phillip R. Purnell, et al.. (2008). Regulation of Id1 Expression by Src: Implications for Targeting of the Bone Morphogenetic Protein Pathway in Cancer. Cancer Research. 68(7). 2250–2258. 67 indexed citations

19.

Yang, Joy C., et al.. (2008). Aberrant Activation of Androgen Receptor in a New Neuropeptide-Autocrine Model of Androgen-Insensitive Prostate Cancer. Cancer Research. 69(1). 151–160. 57 indexed citations

20.

Shi, Xu-Bao, Lingru Xue, Joy C. Yang, et al.. (2007). An androgen-regulated miRNA suppresses Bak1 expression and induces androgen-independent growth of prostate cancer cells. Proceedings of the National Academy of Sciences. 104(50). 19983–19988. 390 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact